Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases

GlobeNewswire February 1, 2022

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 31, 2022

Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire January 10, 2022

Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2022

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 31, 2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 30, 2021

Moore Kuehn, PLLC Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm

Newsfile November 30, 2021

Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development

GlobeNewswire November 17, 2021

Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors

GlobeNewswire November 17, 2021

Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments

GlobeNewswire November 3, 2021

Sarepta Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 2, 2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 29, 2021

Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021

GlobeNewswire October 27, 2021

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock

GlobeNewswire October 13, 2021

Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021

GlobeNewswire October 12, 2021

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

GlobeNewswire October 12, 2021

Sarepta Therapeutics' SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

GlobeNewswire October 11, 2021

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio

GlobeNewswire October 4, 2021

Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire October 4, 2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 30, 2021